Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.78 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.78 |
| ▸ | SCN2B | O60939 | 1/20 | 0.63 |
| ▸ | SCN1A | P35498 | 1/20 | 0.63 |
| ▸ | SCN4A | P35499 | 1/20 | 0.63 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.63 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.63 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.63 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.63 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.63 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31643102 | 1.00 | SCN9A (0.78) | SCN9ACYP2C9SCN5ASCN2BSCN1A | |
| SCHEMBL1109053 | 0.91 | SCN9A (0.64) | SCN9ACYP2C9SCN5ASCN2BSCN1A | |
| Pf-05089771 SCHEMBL25819004 | 0.90 | SCN9A (0.77) | SCN9ACYP2C9SCN5ASCN2BSCN1A | |
| SCHEMBL319734 | 0.89 | SCN9A (0.65) | SCN9ACYP2C9SCN5ASCN2BSCN1A | |
| Hydrochloric Acid SCHEMBL14889660 | 0.88 | SCN9A (0.64) | SCN9ACYP2C9SCN5ASCN2BSCN1A | |
| SCHEMBL17450366 | 0.88 | SCN9A (1.00) | SCN9ACYP2C9SCN5ASCN2BSCN1A | |
| SCHEMBL16531374 | 0.86 | SCN9A (1.00) | SCN9ACYP2C9SCN5A | |
| SCHEMBL1095371 | 0.84 | SCN9A (0.78) | SCN9ACYP2C9SCN5ASCN1ASCN2A | |
| SCHEMBL16531653 | 0.83 | SCN9A (1.00) | SCN9ACYP2C9SCN5ASCN1ASCN2A | |
| Pf-05089771 SCHEMBL21968007 | 0.82 | SCN9A (0.65) | SCN9ACYP2C9SCN5ASCN2BSCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2385938-B1 | SULFONAMIDE DERIVATIVES | PFIZER LTD (GB) | 2015-03-04 | — | — | EP | claimed |
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | claimed |
| US-20130338111-A1 | Sulfonamide Derivatives | ICAGEN, INC. (US) | 2013-12-19 | — | — | US | claimed |
| US-8541588-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2013-09-24 | — | — | US | claimed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | claimed |
| EP-2385938-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited (GB) | 2011-11-16 | — | — | EP | claimed |
| US-8040476-B2 | Display device and method of producing the same | MITSUBISHI ELECTRIC CORPORATION (JP) | 2011-10-18 | — | — | US | claimed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | claimed |
| US-20180346470-A1 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2018-12-06 | — | — | US | disclosed |
| EP-3386983-A1 | 4-(BIPHEN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZINE DERIVATIVES OF FORMULA (I) AS GABA RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF EPILEPSY AND PAIN | Pfizer Limited (GB) | 2018-10-17 | — | — | EP | disclosed |
| EP-3154979-B1 | IMIDAZOPYRIDAZINE DERIVATIVES AS MODULATORS OF THE GABAA RECEPTOR ACTIVITY. | PFIZER LTD (GB) | 2018-03-07 | — | — | EP | disclosed |
| US-9802945-B2 | Imidazopyridazine derivatives as modulators of the GABAA receptor activity | PFIZER LIMITED (GB) | 2017-10-31 | — | — | US | disclosed |
| US-20170305857-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (UK) | 2017-10-26 | — | — | US | disclosed |
| US-20170197965-A1 | Imidazopyridazine Derivatives As Modulators of the GABAA Receptor Activity | PFIZER LIMITED (GB) | 2017-07-13 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
| EP-2385938-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-8040476-B2 | Display device and method of producing the same | MITSUBISHI ELECTRIC CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | SCN9A 73/4885CYP2C9 75/4885SCN5A 19/4885 |
| US-20130338111-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | SCN9A 73/4885CYP2C9 75/4885SCN5A 19/4885 |
| US-20180346470-A1 | CHEMICAL COMPOUNDS | P2RX5, GABRA5, P2RX3 | SCN9A 464/4885CYP2C9 144/4885SCN5A 38/4885 |
| US-20170305857-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | TNNI3, MUSK, MYLK2 | SCN9A 1349/4885CYP2C9 4236/4885SCN5A 485/4885 |
| US-20120149679-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | SCN9A 73/4885CYP2C9 75/4885SCN5A 19/4885 |
| US-20170197965-A1 | Imidazopyridazine Derivatives As Modulators of the GABAA Receptor Activity | GABRA5, GABRA3, GABRA2 | SCN9A 481/4885CYP2C9 287/4885SCN5A 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.